A Phase 1 Study Of The Safety, Pharmacokinetics And Anti-tumor Activity Of Talazoparib, Poly (Adp-ribose) Polymerase (Parp) Inhibitor, In Japanese Patients With Advanced Solid Tumors
Latest Information Update: 26 Aug 2024
At a glance
- Drugs Talazoparib (Primary)
- Indications Advanced breast cancer; Carcinoma; Male breast cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pfizer
- 22 Aug 2024 Status changed from active, no longer recruiting to completed.
- 01 Aug 2022 Planned End Date changed from 1 Jul 2022 to 31 Aug 2024.
- 23 Jun 2021 Results (n=9) assessing safety, pharmacokinetics and preliminary efficacy of talazoparib in Japanese patients with advanced solid tumors, published in the Investigational New Drugs.